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Accepted 18 September 2012AbstractObjective: To assess the clinical response to imiquimod 5% cream in patients with persistent human papillomavirus (HPV) infection after
treatment of genital intraepithelial neoplasia.
Materials and Methods: Imiquimod 5% cream was applied to treat 76 women with persistent HPV after surgical therapy for cervical or vaginal
intraepithelial neoplasia (CIN or VAIN). One sachet of cream was placed in the cervical os and vagina with an applicator twice weekly for 8
weeks. Repeated HPV evaluation and Papanicolaou (Pap) smear and/or biopsy were performed 3 months following treatment completion.
Results: In total, 58 of the 76 patients (76.3%) were clear of HPV infection and had normal Pap smears after administration of imiquimod cream.
Although atypia or mild dysplasia was noted in 15 of the 18 patients (83.3%) with persistent HPV infection after imiquimod cream treatment, the
degree of severity was noticeably less than the initial diagnosis in most of these patients. Persistent HPV positivity was observed in 12 of the 64
patients (18.8%) with CIN and 6 of the 12 patients (50.0%) with VAIN.
Conclusion: Topical imiquimod 5% cream may be beneficial in most cases of genital intraepithelial neoplasia, especially CIN, with persistent
HPV following surgical treatment.
Copyright  2013, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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The standard therapy for genital intraepithelial neoplasia is
surgical, either ablative or excisional. However, these two
forms of therapies merely treat the lesion and not the etio-
logical factor, which is mostly correlated to the underlying
human papillomavirus (HPV). It is reported that patients with
histologically proven complete removal of cervical intra-
epithelial neoplasia (CIN) may have a recurrence [1,2].
Recently pooled long-term follow-up data indicate that treated
women are still at an increased risk for subsequent invasive
cervical cancer, compared to the general population, for at
least 10 years and maybe even up to 20 years after treatment* Department of Obstetrics and Gynecology, Keelung Chang Gung Memo-
rial Hospital, 222 Mai-Chin Road, Keelung, Taiwan.
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http://dx.doi.org/10.1016/j.tjog.2013.10.004[3]. The risk of recurrent CIN is higher in women older than
50 years [4], which is consistent with the observation that viral
persistence increases with age [5]. Thus, the persistence of
HPV infection after treatment of genital intraepithelial
neoplasia should be considered as a greater risk factor of
relapse or progression to a more invasive lesion.
Several epidemiological studies have indicated that
persistently infected women with oncogenic HPV types are
more likely to develop cervical neoplastic lesions [6]. Chua
and Hjerpe found that among recurring cases, a 92% HPV
prevalence was noted at the first follow-up smear 3 months
after cervical conization [7]. It is also reported that patients
with persisting HPV infection after treatment demonstrated a
statistically significant higher rate of recurrences than patients
in whom HPV was successfully eradicated. None of the pa-
tients in whom HPV infection was eradicated developed
recurrent disease [7,8]. Therefore, in addition to genital
cytology and colposcopic examination, HPV testing couldcs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
Patients with persistent HPV infection versus patients with eliminated HPV
infection after topical treatment with imiquimod cream.
Histology Persistent HPV No HPV Total
n ¼ 18 (23.7%) n ¼ 58 (76.3%) n ¼ 76
CIN III 1 14 15
CIN II 3 2 5
CIN I 8 36 44
VAIN II 1 1 2
VAIN I 5 5 10
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apeutic results for genital intraepithelial neoplasia treatment
and to discriminate patients with a higher risk of disease
recurrence.
As aforementioned, current standard therapies have a
limited impact in preventing recurrence. Another important
issue in the control of genital lesions is the treatment of
established HPV infections and HPV-associated diseases.
Imiquimod is a low-molecular-weight imidazoquinoline het-
erocyclic amine that acts as an immune response modifier and
induces cytokines to fight the causative agent of genital le-
sions, the HPV [9e11]. Cytokines are known to stimulate the
induction of natural killer cells, which exhibit a cytotoxic
action to the HPV-infected and carcinogenic cells [12,13].
Although imiquimod 5% cream has been used widely for the
treatment of condyloma acuminate of the vulva, there have
been sporadic reports with a small number of patients using
the drug for the management of high-grade vulvar intra-
epithelial neoplasia (VIN II/III) [14e16], as well as for
vaginal intraepithelial neoplasia (VAIN) [17,18], with
acceptable rates of disease regression. In addition, recent
studies have demonstrated that the immune system plays an
important role in HPV disease regression [19]. Imiquimod has
revealed immunomodulating, antiviral, and antitumor activ-
ities in animal studies [9]. Therefore, the rationale for this type
of therapy is based on the conjecture that multicentric lesions
of the lower genital tract are strongly related to the HPV [20].
The purpose of the present study is to assess the efficacy of
topical imiquimod in patients with persistent HPV infection
after treatment of genital intraepithelial neoplasia and to
evaluate the recurrence during subsequent long-term follow-
up.
Materials and methods
We reviewed surgical cases with available records in the
Department of Obstetrics and Gynecology at Keelung Chang
Gung Memorial Hospital from January 2006 to December
2009. Those women with persistent HPV infection following
both surgical treatment for CIN or VAIN and treatment with
imiquimod 5% cream (Aldara; 3M Health Care Limited,
Loughborough, UK) thereafter were evaluated. Treatment was
off-label because vaginal and/or cervical use is not a listed
indication for imiquimod 5% cream. The use of vaginal or
cervical imiquimod 5% cream was undertaken simply to treat
patients and was not done as a research project. However, a
general consent form was signed by each patient prior to
treatment. In addition, the retrospective study was approved by
the Chang Gung Memorial Hospital Ethical Medicine
Committee.
The preoperative diagnoses were taken from the patients’
colposcopically directed biopsies. For those whose initial bi-
opsy showed CIN II or III, the diagnoses were further
confirmed by the pathological specimens resected by coniza-
tion. Local CO2 vaporization of the vagina or cervix was
performed for 10 of the patients with VAIN I, two with VAIN
II and 44 with CIN I. Therapeutic cold knife conization wasdone for five patients with CIN II and 15 with CIN III, which
was confirmed with the complete resection of cervical lesions
in all of these patients. Investigation of HPV infection was
performed 1 month prior to and after surgical therapy.
Cervical or vaginal sampling for HPV DNAwas performed
with the Digene cervical sampler. DNA specimens were
collected by inserting the Digene brush 1e1.5 cm into the
cervical os, until the largest outer bristles of the brush touched
the ectocervix or upper vagina. Three full rotations were done,
performed in a counter-clockwise direction. The brush was
then inserted into the bottom of the transport tube, with its
shaft snapped off at the score line and the tube was capped
securely. The Hybrid Capture II HPV DNA test (Digene
Corporation, Gaithersburg, MD, USA) was used for the
detection of HPV. This hybridization antibody capture assay
uses chemiluminescence to quantitatively detect the presence
of low risk (6, 11, 42, 44) and high/intermediate risk (16, 18,
31, 33, 35, 45, 51, 52, 56) HPV types in cervical or vaginal
swabs. According to the manufacturer’s instructions, the
clinical relative sensitivity is 90.1% and the clinical relative
specificity is 95.6%.
Because the positive HPV tests were noted after local
treatment, the patients sought topical treatment via imiquimod
5% cream. One sachet of cream (0.25 g) was placed in the
entire cervix and/or entire vagina with an applicator twice
weekly for 8 weeks. The procedure was performed by Dr
Chen. Three months after the imiquimod treatment was
administered, the patients had follow-up Papanicolaou smears
and HPV tests done. The patients were also asked if they
experienced any discomfort during or after the cream
treatment.
Fisher’s exact tests were used to evaluate the association of
menopausal status, location of lesions, surgical method and
lesion grade with HPV clearance/persistence, after treatment
using imiquimod cream.Results
A total of 76 patients with CIN or VAIN, who had persis-
tent HPV infection after surgical therapy, participated in this
study. After topical imiquimod cream treatment, no expression
of HPV was confirmed in 58 (76.3%) of the patients. Of the 18
patients with persistent HPV infection, one patient had CIN
III, three had CIN II after conization, eight had CIN I and six
had VAIN I after local CO2 vaporization (Table 1).
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patients (83.3%) with persistent HPV infection after imiqui-
mod cream treatment, the degree of severity was noticeably
less than the initial diagnosis in most of these patients. After
treatment, atypia was found in 10 of the patients (1 with CIN
III, 1 with CIN II, 3 with CIN I, 1 with VAIN II and 4 with
VAIN I) and CIN I was noted in two patients with CIN II and
three with CIN I.
Univariate Fisher’s exact tests showed a significantly higher
proportion of persistent HPV infection in the patients with
vaginal lesions after treatment with imiquimod cream
( p ¼ 0.029). Menopausal status, pretreatment surgical
methods and lesion grade were not associated with HPV
clearance/persistence (Table 2).
Discussion
Although different conservative methods for the treatment
of genital preinvasive lesions have been developed and
extensively applied, the persistence of HPV infection after
treatment and its relationship with the lesion evolution has
become an important issue. The present review demonstrated
that after imiquimod 5% cream treatment, clearance of HPV
infection occurred in 76.3% of the patients with CIN or VAIN.
Imiquimod cream seems to be less effective in patients with
VAIN than in those with CIN. Although such efficacy is
encouraging, several factors concerning these results still
should be examined.
Recent studies have been developed so as to evaluate the
feasibility of using imiquimod to treat patients with VIN,
VAIN, and CIN. Most of these studies have focused on the
histological regression of the lesion, but not on the clearance
of the HPV infection like our study does. Diaz-Arrastia et al
[21] treated eight patients with genital intraepithelial
neoplasia, in which previous standard therapies had failed,
with topical imiquimod 5%. Included in these eight cases were
two patients with cervical dysplasia, two with vaginal
dysplasia and four with vulvar dysplasia. They found six of the
patients to be responsive, both partially and completely, to
treatment. Three patients had recurrences but all were suc-
cessfully re-treated with imiquimod 5% cream. In addition toTable 2
Possible factors affecting topical treatment with imiquimod cream.
Persistent HPV, n (%) No HPV, n (%) p
Menopause 0.088
Yes 12 (66.7) 26 (44.8)
No 6 (33.3) 32 (55.2)
Location of lesion 0.029
Cervix 12 (66.7) 52 (89.7)
Vagina 6 (33.3) 6 (10.3)
Surgical method 0.4528
Conization 4 (22.2) 16 (27.6)
CO2 laser 14 (77.8) 42 (72.4)
Lesion grade 0.5767
LSIL 13 (72.2) 41 (70.9)
HSIL 5 (27.8) 17 (29.1)
HSIL ¼ high-grade squamous intra-epithelial lesion;
LSIL ¼ low-grade squamous intra-epithelial lesion.the effects on the regression of the lesion, they demonstrated
an increase of 20,50-oligoadenylate synthetase RNA expression
after imiquimod treatment, which may potentially be an
important mechanism of action of imiquimod on antiviral
activity. In a study where topical imiquimod was used to treat
25 patients with VIN and who tested positive for HPV DNA
[22], they revealed that HPV had been cleared in 15 of the
patients (60%). In addition, the research noted a strong asso-
ciation between viral clearance and histological regression.
This is compatible to our results, in which HPV clearance
reached up to 76.3% and no persistent nor abnormal histo-
logical changes were noted in those HPV cleared by imiqui-
mod. The efficacy of imiquimod in clearing HPV infection
seems to be elevated in our study. Although there were
controversial results regarding the use of surgical treatment to
eradicate the HPV infection [8,23], further investigation is
required to examine whether the preimiquimod surgical
treatment may have strengthened the effects of the imiquimod
or not.
Although the use of imiquimod in the cervix has been
questioned due to the difference in the anatomic and imiqui-
mod characteristics of the external skin and vagina, the
beneficial effects of imiquimod on the cervix have been re-
ported [21,24]. In the present review, the effect of imiquimod
on HPV clearance was significantly better on CIN than on
VAIN. Although HPV had only cleared in six (50%) of the 12
patients with VAIN, the histological regression of VAIN could
reach 100%, except for the five patients with atypia after
imiquimod treatment. Similar results were also noted in other
studies [17,18], except they did not reveal the effect of treat-
ment on HPV clearance. Buck et al [17] demonstrated that 36
(86%) of the 42 patients with VAIN I were clear of any VAIN
lesion after receiving one imiquimod course (each course
consists of a single administration weekly for 3 weeks); five
patients were cleared after two treatment courses and one
patient after three courses. In another study of seven patients
with positive HPV and VAIN II/III, six patients were found to
have either VAIN I or simple HPV infection and one patient
had regression lesion from VAIN III to VAIN II after imi-
quimod treatment [18]. Because the case numbers in all of
these studies, including our review, are too minute, further
investigation is still needed to determine and confirm whether
the effects of imiquimod on CIN would be superior to that on
VAIN. However, imiquimod may have an effect on the HPV
clearance and regression of the genital intraepithelial
neoplasia.
It is not known why some patients responded to imiquimod
whereas others did not. It has been considered that the
persistence of HPV might be associated and correlated with
several factors, including the presence of high-risk types, viral
load, age, number of sexual partners, sex hormone regulation
and host immunity [25]. van Seters et al [22] evaluated the
effects of imiquimod on vulvar dysplasia, in which HPV had
cleared in 14 of the patients with HPV type 16 and one with
type 33. They demonstrated that there was no significant as-
sociation between HPV type and viral outcome. In this review,
we did not examine the HPV type, but the HPV load did not
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the effect on HPV clearance was also not related to meno-
pausal status, surgical method and/or histological grading of
the lesion. Because imiquimod acts as an immune response
modifier, further evaluation is needed to determine whether the
immune response of patients to imiquimod plays an important
role or not and why patients would have differing responses to
the treatment.
This review differs from other studies in the respect that
these patients received standard surgical therapy prior to
imiquimod treatment. Thus, a major limitation is that there are
no randomized controlled trials. Another limitation is that a
lack of response to imiquimod treatment does not seem to be
associated with a higher risk of lesion progression, but that
may be related to the duration of the follow-up. Therefore,
from this review, it can be concluded that the effect of com-
bined imiquimod treatment and standard surgical therapy for
CIN and VAIN and the efficacy of imiquimod for HPV
clearance are worth further investigation. However, longer
follow-up periods are needed to make any conclusion
regarding the effectiveness, recurrence rates and recurrence
free interval duration of this treatment.
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